Test Code COM Complement, Total, Serum
Reporting Name
Complement, Total, SUseful For
Detection of individuals with an ongoing immune process
First-tier screening test for congenital complement deficiencies
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Serum RedSpecimen Required
Patient Preparation: Fasting preferred.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. After sample has clotted on wet ice, centrifuge at 4° C and aliquot serum into 5 mL plastic vial.
3. Within 30 minutes of centrifugation, freeze specimen. Sample must be placed on dry ice if not frozen immediately.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum Red | Frozen | 28 days |
Reference Values
30-75 U/mL
Day(s) Performed
Monday through Friday
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86162
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
COM | Complement, Total, S | 4532-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
COM | Complement, Total, S | 4532-8 |
Interpretation
Low levels of total complement (total hemolytic complement) may occur during infections, disease exacerbation in patients with systemic lupus erythematosus, and in patients with immune complex diseases such as glomerulonephritis.
Undetectable levels suggest the possibility of a complement component deficiency. Individual complement component assays are useful to identify the specific deficiency.
Clinical Reference
1. Daha MR. Role of complement in innate immunity and infections. Crit Rev Immunol. 2010;30(1):47-52. doi:10.1615/critrevimmunol.v30.i1.30
2. Prohaszka Z, Varga L, Fust G. The use of 'real-time' complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. Br J Haematol. 2012;158(3):424-425. doi:10.1111/j.1365-2141.2012.09168.x
3. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014;123(24):3733-3738. doi:10.1182/blood-2013-12-547067
4. Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem. 2016;77:1-75. doi:10.1016/bs.acc.2016.06.001
Report Available
1 to 2 daysMethod Name
Automated Liposome Lysis Assay